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ABSTRACT 
 
Objective: Protease activated receptor 4 (PAR4) is a key regulator of platelet reactivity and 
is encoded by F2RL3 which has abundant rare missense variants. We aimed to provide 
proof of principle that rare F2LR3 variants potentially impact on platelet reactivity and 
responsiveness to PAR1 antagonist drugs and to explore underlying molecular mechanisms.  
 
Approach and results: We identified six rare F2RL3 missense variants in 236 cardiac 
patients, of which the variant causing a tyrosine 157 to cysteine substitution (Y157C) was 
predicted computationally to impact most on PAR4 structure. Y157C platelets from three 
cases showed reduced responses to PAR4-activating peptide and to α-thrombin compared 
to controls, but no reduction in responses to PAR1 activating peptide.  Pre-treatment with the 
PAR1 antagonist vorapaxar caused lower residual α-thrombin responses in Y157C platelets 
than in controls, indicating greater platelet inhibition. HEK293 cells transfected with a PAR4 
Y157C expression construct had reduced PAR4 functional responses, unchanged total 
PAR4 expression but reduced surface expression. PAR4 Y157C was partially retained in the 
endoplasmic reticulum and displayed an expression pattern consistent with defective N-
glycosylation. Mutagenesis of Y322, which is the putative hydrogen bond partner of Y157, 
also reduced PAR4 surface expression in HEK293 cells.  
 
Conclusions: Reduced PAR4 responses associated with Y157C result from aberrant 
anterograde surface receptor trafficking, in part because of disrupted intra-molecular 
hydrogen bonding. Characterisation of PAR4 Y157C establishes that rare F2RL3 variants 
have the potential to markedly alter platelet PAR4 reactivity particularly after exposure to 
therapeutic PAR1 antagonists.  
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NON-STANDARD ABBREVIATIONS AND ACRONYMS 
 
AFU Arbitrary fluorescence units 
BW Ballesteros-Weinstein 
ECL Extracellular loop 
EEA1 Early endosomal antigen 1 
ER Endoplasmic reticulum 
GPCR G protein-coupled receptor 
ICL Intracellular loop 
IP3 Inositol 1,4,5 triphosphate 
LTA Light transmission aggregation 
MA Maximum aggregation 
MFI Median fluorescence intensity 
PCR Polymerase chain reaction 
PAR1 Protease activated receptor 1 
PAR4 Protease activated receptor 4 
PRP Platelet rich plasma 
TM Transmembrane  
WP Washed platelets 
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INTRODUCTION 
 
Protease activated receptors (PARs) are G protein-coupled receptors (GPCRs) that are 
critical mediators of haemostasis and inflammation in blood and vascular cells. 1 Human 
platelets express both PAR1 and PAR4, which mediate activation by the potent physiological 
agonist thrombin through stimulation of Gαq and phospholipase Cβ, leading to the 
mobilisation of cytoplasmic Ca2+. 2, 3 PAR1 has a greater affinity for thrombin and mediates 
rapid Ca2+ mobilisation and platelet activation. By contrast, PAR4 activation requires higher 
concentrations of thrombin and leads to gradual and sustained Ca2+ mobilisation, which may 
be necessary for stable platelet thrombus formation. 4, 5 The importance of the PARs for 
platelet activation is illustrated by the efficacy of PAR1 and PAR4 antagonists as anti-
thrombotic agents, 6, 7 but also by observations that clinical use of the PAR1 antagonist 
vorapaxar increases the risk of intracranial bleeding. 8, 9 
 
Platelet reactivity to activating agonists is a predictor of adverse cardiovascular events, 
particularly in patients receiving anti-platelet drugs for secondary prevention of arterial 
thrombosis. 10, 11 Although platelet reactivity shows large variation across populations, it is a 
reproducible phenotype within individuals and has been estimated as 60-70% heritable. 12 
Genome wide association studies have identified common variants in several genes that 
account for some of the inter-individual differences in platelet reactivity to epinephrine, 
collagen and ADP. 13, 14 Smaller candidate gene studies have also identified associations 
between platelet reactivity to PAR agonists and common variants in F2R that encodes PAR1 
15, 16 and in F2RL3 that encodes PAR4. 17 Increased platelet PAR4 reactivity has been 
observed in African-American compared with European-American populations, suggesting a 
race-dependent genetic effect. 18 Part of this difference is accounted for by increased platelet 
levels of phosphatidylcholine transfer protein in African-American populations, which affects 
PAR4 reactivity indirectly. 18 However, there is also a contribution from the common F2RL3 
coding variant rs773902 that predicts an alanine 120 to threonine substitution (A120T) and is 
associated with increased PAR4 reactivity. 19 The rs773902 variant was observed at a 
frequency of 0.63 in an African-American population compared to 0.19 in European-
Americans, and accounted for 48% of the overall population variance in PAR4 reactivity. 19 
 
In an analysis of population genetic databases, we recently showed that in addition to the 
common rs773902 variant, the F2RL3 coding region also contains diverse rare genetic 
variants (global minor allele frequency <0.01), and that these occurred at a higher frequency 
than in other platelet GPCR genes. 20 F2RL3 also contained a higher proportion of rare 
variants that were predicted computationally to be deleterious to receptor function compared 
to benign variants. 20 Together, these observations suggest that rare F2RL3 variants may 
contribute to the population variance in PAR4 reactivity, alongside common variants such as 
rs773902. Since some rare F2RL3 variants in population databases are predicted to have a 
large influence on the expression level or function of PAR4, 20 there may be a strong effect in 
individual patients on characteristics such as platelet haemostatic function or 
responsiveness to anti-thrombotic drugs that target the PAR pathway. 
 
In order to provide proof of principle that rare F2RL3 variants have the potential to impact on 
platelet PAR4 reactivity, we sequenced the F2RL3 gene in a sample cohort of cardiac 
surgery patients at the Bristol Heart Institute and then evaluated the observed variants using 
computational prediction tools. The variant predicting a tyrosine 157 to cysteine (Y157C) 
substitution, which had the greatest predicted effect on PAR4 structure, was then analysed 
experimentally using platelets from PAR4 Y157C cases and transfected HEK293 cells.  
 
MATERIALS AND METHODS 
The study design and experimental methods are described in the online-only Data 
Supplement. 
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RESULTS 
 
Characteristics of cases and F2RL3 genotypes  
In a sample cohort of 236 cardiac surgery patients, (median age 69 years; 200 (85%) male; 
227 (96%) Caucasian European), we identified seven different missense single nucleotide 
variants in the F2RL3 coding region (Table 1). These included the common rs773902 
(encoding PAR4 A120T), which has an allele frequency of 0.22 in Europeans in the Exome 
Aggregation Consortium Browser (ExAC) dataset 21 and occurred at a frequency of 0.14 in 
the study cohort. The remaining six variants were present as heterozygous alleles in a total 
of nine index cases and had MAFs of <0.01 in the ExAC dataset. 21 
 
The variants predicting alanine 82 to threonine, alanine 286 to threonine, proline 310 to 
leucine and valine 335 to leucine substitutions in PAR4 were classified as benign by meta-
analysis of six different computational prediction tools using the PredictSNP consensus 
classifier 22 (Table 1 and Supplemental Table I). These substitutions were also predicted to 
have minimal impact on the structure of PAR4 determined from a homology model 
generated from the antagonist-bound PAR1 structure 23 (Supplemental Figure S1). The 
variant predicting a phenylalanine 296 to leucine (F296L) substitution was identified as 
deleterious to PAR4 by PredictSNP, although with a low likelihood score (Table 1 and 
Supplemental Table S1). In the PAR4 homology model, F296 projected centrally into the 
PAR4 transmembrane (TM) domain bundle, but was not predicted to contribute inter-TM 
domain hydrogen bonding (Supplemental Figure I). 23 
 
The remaining variant, that predicted tyrosine 157 to cysteine substitution (Y157C) was 
present in only two of the 57,476 F2RL3 alleles reported in the ExAC database, and was 
classified as deleterious to PAR4 by PredictSNP with a high likelihood score (Table 1 and 
Supplemental Table S1). In the PAR4 homology model, Y157 projected centrally from TM 
domain 3 and was predicted to form a hydrogen bond with tyrosine 322 (Y322) in TM 
domain 7 (Figure 1A and B), thereby contributing to the PAR4 inter-TM domain contacts. 
Since this indicated that Y157C had a greater potential structural impact than the other 
variants observed in the study cohort, the index case harbouring Y157C and pedigree 
members were evaluated further. 
 
Clinical characteristics and platelet aggregation responses  
The Y157C index case was a 66 year-old Caucasian male non-smoker (Y157C.1) who 
underwent elective coronary artery bypass grafting for symptomatic triple vessel disease. He 
had a history of upper gastrointestinal bleeding during previous aspirin treatment and 
intermittent bleeding from colonic diverticular disease, but no other bleeding symptoms. 
Y157C was also identified in two sons aged 39 and 36 years (Y157C.2 and Y157C.3; 
Supplemental Figure II) who had no history of cardiovascular disease or abnormal bleeding. 
Y157C.1, but not Y157C.2 or Y157C.3 harboured the heterozygous common variant 
rs773902 (PAR4 A120T). None of the study subjects were receiving aspirin or other drugs 
known to influence platelet function. There was no family history of abnormal bleeding. 
 
Compared to controls with no rare F2RL3 variants, platelets from the three Y157C cases all 
showed reduced maximum amplitude (MA) of LTA with 100 and 150 µM PAR4-activating 
peptide (PAR4-AP) and with 0.01 U/ml α-thrombin. Responses to PAR1-activating peptide 
(PAR1-AP) at concentrations in the range 1-10 µM were unchanged compared with controls. 
Shape change and lag phase of the aggregation responses to all the agonists were 
unchanged (Figure 2A and B). In order assess the impact of Y157C on platelet inhibition by 
vorapaxar, we first showed that pre-incubation of control platelets with 5 µM vorapaxar 
resulted in an approximately 90% reduction in LTA responses with 10 µM PAR1-AP 
(Supplemental Figure III), similar to that in healthy volunteers receiving therapeutic doses of 
vorapaxar. 24 At this concentration, LTA responses to 150 µM PAR4-AP were not reduced, 
indicating selective antagonism of PAR1. Pre-incubation of control platelets with 5 µM 
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vorapaxar caused an approximately 20% reduction in the LTA response with 0.1 U/mL α-
thrombin, consistent with loss of the PAR1 component of the α-thrombin response (Figure 
2C, 2D and Supplemental Figure S3). However with Y157C platelets, pre-incubation with 
vorapaxar almost completely abolished the LTA response to 0.1 U/mL α-thrombin (Figure 
2D), indicating greater inhibition of platelet reactivity. 
 
Other platelet activation responses and PAR4 expression  
Compared with controls, platelets from all three Y157C cases showed reduced cytoplasmic 
Ca2+ mobilisation with PAR4-AP at concentrations of 50-1000 µM (Figure 3A). No significant 
changes in Ca2+ mobilisation were observed in Y157C platelets compared to controls in 
response to 1-100 µM PAR1-AP or to 0.5-5 U/ml α-thrombin (Figure 3B and C and 
Supplemental Figure IV).  Integrin αIIbβ3 activation and α-granule release with 150 µM 
PAR4-AP were both reduced in Y157C platelets compared with controls but responses with 
5 µM PAR1-AP were unchanged (Figure 3D). 
 
In Western blots of lysates from Y157C platelets and from controls, PAR4 and PAR1 
migrated as bands of approximately 40 and 70 kDa respectively (Figure 4A).  When 
expressed relative to the corresponding tubulin bands, the densities of the PAR4 and PAR1 
bands were unchanged in Y157C platelets compared with controls (Figure 4B), indicating 
that the reduced PAR4 reactivity was not the result of diminished PAR4 synthesis or 
abnormal catabolism.  
 
PAR4 Y157C expression and function in HEK293 cells 
In order to investigate further the mechanism of the reduced PAR4 reactivity suggested in 
the platelet experiments, we next studied HEK293 cells transfected with Y157C variant 
(PAR4 Y157C) or non-mutagenised (PAR4 WT) expression constructs with a CFP tag is 
expressed at the PAR4 carboxyl-terminus. Total expression of the PAR4-CFP fusion protein, 
determined from the CFP fluorescence, was unchanged in PAR4 Y157C cells compared to 
PAR4 WT cells (Figure 5A), similar to the findings in Y157C platelets. However, we 
additionally found that surface PAR4 expression, assessed by measuring binding of an 
antibody recognising the PAR4 extracellular domain, was reduced in PAR4 Y157C cells 
compared to PAR4 WT cells (Figure 5B).  
 
Stimulation of HEK293 cells transfected with empty vector with PAR4-AP did not increase 
the cytoplasmic Ca2+ concentration. However, stimulation of PAR4 WT cells caused 
significant Ca2+ responses with PAR4-AP at concentrations of 10 µM-1 mM (Figure 5C), 
similar to the range previously shown to increase cytoplasmic Ca2+ in control platelets. This 
confirmed that PAR4 WT expressed as a CFP fusion protein retained functional activity.  
Compared to the PAR4 WT cells, the PAR4 Y157C cells showed reduced cytoplasmic Ca2+ 
mobilisation with 50-500 µM PAR4-AP (Figure 5C) and less accumulation of inositol 
phosphate (IP3) with 10-100 µM PAR4-AP (Figure 5D). This confirmed that the defect in 
surface expression of PAR4 Y157C in the HEK293 cells was associated with reduced PAR4 
reactivity. 
 
Trafficking of PAR4 Y157C in HEK293 cells 
In order to investigate the defect in surface expression further, the PAR4-CFP fusion 
proteins were visualised in both the WT and Y157C cells by immunofluorescence confocal 
microscopy.  In the WT cells, PAR4-CFP was localised at the cell membrane, but also to 
discrete structures within the cytoplasm. By contrast, in the Y157C cells, PAR4-CFP was 
diffusely localised to the peri-nuclear region, with minimal surface expression (top panels of 
Figure 6A and B). In order to further define the abnormal distribution of PAR4 Y157C, the 
HEK293 cells were also visualised after incubating with antibodies recognising early 
endosome antigen 1 (EEA1), a marker of the endosomes that mediate surface receptor 
internalisation, and calnexin, an endoplasmic reticulum (ER) exit marker. Whilst in the WT 
cells, PAR4-CFP co-localised with EEA1-positive compartments, in the Y157C cells, there 
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was less co-localisation (Figure 6A and 6C). By contrast, there was greater co-localization 
with calnexin in the Y157C cells than in the WT cells (Figure 6B and 6C), suggesting that 
PAR4 Y157C undergoes abnormal anterograde trafficking between the ER and cell 
membrane.  
 
In Western blots of lysates from both the WT and Y157C cells, the CFP fusion proteins 
migrated as prominent bands of approximately 55 kDa, comparable with the predicted 
molecular weight of PAR4-CFP. In the WT cell lysates, PAR4-CFP also migrated as a series 
of broad bands between 60 and 80 kDa, consistent with post-translationally modified forms. 
25 Levels of these modified forms were reduced in the Y157C cell lysates, similar to a control 
cell line expressing PAR4 in which the consensus N-linked glycosylation site in the amino-
terminal region of PAR4 had been removed by mutagenesis (PAR4 N56A; Figure 6D). PAR-
CFP expression in the N56A cells was also absent at the cell membrane (Figure 6F). These 
data are consistent with receptor retention in the ER and further confirm the inability of PAR4 
Y157C to be efficiently transported to the plasma membrane.  
   
In the PAR4 homology model, Y157 was predicted to form a hydrogen bond with Y322 in TM 
domain 7, which is essential for the structural integrity of related class A GPCRs. We tested 
the effect of disruption of this bond using HEK293 cells transfected with a PAR4 Y322A 
expression, in which the Y157-Y322 hydrogen bond was disrupted by mutagenesis of Y322. 
Similar to PAR4 Y157C, Western blots of lysates from the Y322A cells showed reduced high 
molecular weight PAR4-CFP forms (Figure 6E).  There was also reduced cell surface 
expression in the Y322A cells compared to the WT cells, and cytoplasmic retention in a 
similar distribution to the Y157C cells (Figure 6F). Together, this suggests that PAR4 Y322A 
also undergoes defective anterograde trafficking towards the cell membrane and highlights 
the importance of the Y157-Y322 hydrogen bond for this process. 
 
 
DISCUSSION 
 
We have demonstrated that in a small cohort of 236 cardiac patients, nine cases harboured 
six different rare missense variants in the PAR4 gene F2RL3. This observation is consistent 
with our previous analysis of the 1000 genomes and Exome Sequencing Project population 
databases, which suggested that F2RL3 was genetically diverse and that when considered 
together, rare F2RL3 variants may be abundant at population level. 20  
 
Amongst the rare variants identified in the study cohort, sequenced based computational 
analysis using the PredictSNP consensus classifier identified two as potentially impactful to 
PAR4 reactivity. These included F296L, which is predicted to disrupt the conserved 
FxxCW/FxP motif in the PAR4 TM domain 6 that mediates activation of related class A 
GPCRs. 26 Substitution of PAR4 F296 with valine (F296V), is a common variant in African-
Africans (MAF 0.06) 21 and has been shown previously to influence PAR4 reactivity,19  
suggesting that F296L may also have a functional impact. A second variant Y157C, was 
predicted to disrupt a hydrogen bond between TM domains 3 and 7 in the PAR4 homology 
model. Inter-TM domain hydrogen bonds have been proposed as essential for class A 
GPCR folding, 23, 27 suggesting high impact effect. We acknowledge that computational 
analysis and structural homology modelling may be insensitive to some impactful variants, 
as illustrated by the failure of these methods to identify the A120T as a change of function 
variant. 19 However, we concluded that Y157C was likely to have a greater effect on PAR4 
reactivity than the other variants in the study cohort, and select this variant for further 
analysis in this proof-of-concept study. 
 
Consistent with this prediction, we found that platelets from the Y157C index case and from 
the two Y157C pedigree members showed reduced responses to PAR4-AP when compared 
with controls in multiple functional assays. By contrast, responses to PAR1-AP were 
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unchanged. Since both PAR4 and PAR1 signal predominantly through Gαq in platelets, 
2, 3 
this is most consistent with a defect at PAR4 receptor level. Y157C platelets also showed 
reduced functional responses to α-thrombin, in keeping with the requirement for both PAR4 
and PAR1 activation for the full platelet response to this agonist. 2 The preservation of 
PAR1-AP responses in the PAR4 Y157C platelets is less consistent with previous 
observations in transfected cell models that PAR1-PAR4 heterodimer formation is necessary 
for full PAR1 expression and function 28. It is not possible to resolve from these functional 
data whether the heterozygous Y157C substitution in the cases disrupts PAR4 homodimer 
formation 29, which could contribute to the loss of PAR4 responsiveness phenotype. 
 
The common coding PAR4 A120T variant (rs773902), has previously been associated with 
gain of PAR4 receptor function. 19 Since the index case Y157C.1 was heterozygous for 
A120T, this may have modified the phenotype of platelets from this case. However, despite 
the presence of A120T, platelets from Y157C.1 showed reduced reactivity when compared 
to the control group of which 80% were homozygous for the reduced function A120 allele. 
Moreover, there were no detectible differences in the PAR4 reactivity of platelets from 
Y157C.1 compared to the other Y157C cases who did not harbour A120T. Other potential 
modifiers of the PAR4 reactivity include non-coding F2RL3 variants, 17 and other regulators 
such as miRNA 18 which potentially affect PAR4 expression level. These were also unlikely 
to have impacted on the reduced PAR4 reactivity in the Y157C platelets since there was no 
reduction in total PAR4 expression compared to controls. Together, these observations 
suggest that Y157C has a larger impact on platelet PAR4 reactivity compared to other 
potential modifiers. We acknowledge that statistical proof of an association between Y157C 
and reduced PAR4 reactivity is hampered by the small number of affected cases, similar to 
other rare variant studies. However, we have also analysed Y157C using HEK293 cells, 
which do not express endogenous PAR4 and are an established PAR expression model. 19, 
25 Our demonstration of reduced PAR4 reactivity in HEK293 cells expressing PAR4 Y157C 
provides strong evidence that Y157C is causally associated with the platelet phenotype and 
that this effect is not dependent on other modifiers. 
 
It is significant that Y157C was associated with gastrointestinal bleeding only during aspirin 
treatment in the index case Y157C.1, and that the pedigree members with Y157C had no 
abnormal bleeding. This suggests that heterozygosity for Y157C alone is insufficient to 
disrupt clinical haemostasis. However, in the presence of the PAR1 antagonist vorapaxar ex 
vivo, we found a greater inhibitory effect on the platelet thrombin response in the Y157C 
cases than in controls. This finding is consistent with impairment of both PAR1 and PAR4 
thrombin activation pathways in the Y157C platelets. Vorapaxar is currently approved by the 
US Food and Drug Administration for the secondary prevention of cardiovascular disease in 
selected patients, 30 but was associated with abnormal bleeding in the pivotal clinical trials. 8, 
9 Our findings raise the possibility that loss-of-function F2RL3 variants could be potential 
pharmacogenetic markers of increased anti-thrombotic effect and of bleeding during anti-
platelet treatment, particularly with PAR1 antagonists and possibly with emerging drugs that 
target PAR4. 6, 31 However, this requires further experimental confirmation.  
 
Using HEK293 cells, we studied the expression and function of PAR4 Y157C with a CFP tag 
appended to the carboxyl-terminus that has previously been shown not to disrupt cellular 
localisation or PAR4 functional responses. 25, 28 Although there may have been a small 
reduction in total receptor expression in this overexpression model, we showed that the 
Y157C substitution resulted in much more marked reduction of surface expression of PAR4, 
thereby reducing the availability of receptor to respond extracellular agonists. Consistent 
with this, PAR4 Y157C showed greater co-localisation than PAR4 WT with the ER exit-
marker calnexin, but less co-localisation with EEA1, which is a marker of endosomes that 
mediate GPCR internalisation after surface membrane expression. 32 Compared to PAR4 
WT, there were also less high molecular weight forms of PAR4, similar to mutagenized 
PAR4 N56A, which is not glycosylated because of the absence of a consensus N-
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glycosylation site. 25 Correct anterograde trafficking of cargo through the ER and Golgi is 
usually required for full N-glycosylation. 33 Therefore, the simplest explanation for these 
observations is that aberrant folding of PAR4 caused by the Y157C substitution leads to 
failure of trafficking beyond the ER, thereby reducing N-glycosylation and impairing cell 
surface expression. 
 
There are several potential explanations of how the Y157C substitution could alter PAR4 
folding sufficiently to disrupt anterograde trafficking. One possibly is that folding is disrupted 
by non-native disulphide bond formation by the new cysteine at position 157. This cannot be 
excluded from our data, although there were no candidate binding partners for cysteine 157 
in the homology model of the correctly folded receptor. A more plausible explanation is that 
abnormal receptor folding is caused by loss of the predicted hydrogen bond between Y157 in 
TM domain 3 and Y322 in TM domain 7. These binding partners are conserved in class A 
GPCRs and contribute to the network of inter-TM domain interactions which maintain 
receptor stability in both inactive and active states. 27 In support of this, we showed that 
disruption of this hydrogen bond by mutagenesis of the cognate Y157 binding partner Y322, 
resulted in accumulation of PAR4 in the cytoplasm and reduced high molecular forms, 
similar to PAR4 Y157C. It is noteworthy that mutagenesis of the homologous Y353 residue 
in PAR1 also resulted in abnormal surface receptor expression. 23  
 
We conclude that reduced PAR4 reactivity in platelets from the study cases is most likely a 
direct effect of the rare Y157C substitution in F2RL3.  At least in HEK293 cells, this is mostly 
a consequence of reduced cell surface PAR4 expression arising from defective anterograde 
trafficking, most likely caused by loss of the Y157-Y322 hydrogen bond and abnormal 
receptor folding. It is noteworthy that mutagenesis of residues that are homologous to Y157 
in other class A GPCRs, such as the P2Y purinoreceptor 1 34 and adenosine receptor A1, 35 
reduced receptor ligand binding, but did not affect surface expression. Therefore, although 
reduced surface expression provides an adequate explanation for loss of PAR4 reactivity in 
the Y157C cells, an additional functional defect in any correctly trafficked PAR4 Y157C 
cannot be excluded from our data. It is a limitation of our study that in the limited number of 
blood samples available from the Y157C cases, we were unable to reliably resolve whether 
platelet surface PAR4 expression was diminished. 
 
To our knowledge, Y157C is the first naturally occurring rare PAR4 variant to have 
undergone mechanistic characterisation. The association between Y157C and reduced 
platelet PAR4 reactivity establishes the principle that rare F2RL3 variants potentially 
contribute to inter-individual differences in platelet function and responses to therapeutic 
PAR antagonists. 
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SINGIFICANCE OF THIS RESEARCH 
Protease activated rceptor 4 (PAR4) mediates platelet activation by thrombin, and is a 
potential target for anti-thrombotic drugs. Rare varaints in the PAR4 gene (F2RL3) are a 
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potential source inter-individual differences in platelet reactivity, yet the impact of these is 
unknown.  Here we provide  proof-of-principle that rare F2RL3 varaints have a high potential 
impact on platelet reactivity by characterising a variant predicting a tyrosine 157 to cysteine 
substitution (Y157C) in PAR4. We show that heterozygous Y157C  platelets have reduced 
PAR4 activation responses and greater levels of inhibition with the therapeutic PAR1 
antagonist vorapaxar compared to controls.  In cell models the Y157C substitution causes 
reduced PAR4 activation responses by altering anterograde trafficking of receptor to the 
surface membrane. This first detailed characterisation of a high impact PAR4 variant 
highlights that rare genetic variants could be potential risk factors for bleeding, particularly 
during anti-thrombotic therapies that target the PAR pathway. 
 
FIGURE LEGENDS 
Figure 1. Structural interactions of PAR4 Y157  
(A) In a PAR4 homology model based on the antagonist-bound PAR1 structure, Y157 
projects centrally from transmembrane (TM) domain 3 into the TM domain bundle. (B) A 
higher resolution image showing the close proximity and likely formation of a hydrogen bond 
between the side chains of Y157 and Y322 in TM7. TM=transmembrane domain; ECL1- 
extracellular loop 1. Superscript indicates Ballesteros-Weinstein numbering. 
!!
Figure 2. Light transmission aggregation responses in Y157C platelets. 
(A) Representative light transmission aggregation (LTA) responses of platelets from Y157.1 
and a control in response to 150 µM PAR4-AP, 0.01 U/mL α-thrombin or 5 µM PAR1-AP. (B) 
Maximum amplitude (MA) of LTA responses to PAR4-AP, α-thrombin and PAR1-AP. (C) 
Representative LTA responses of platelets from Y157C.1 and control, pre-incubated with 
vehicle (left panel) or with 5 µM vorapaxar (right panel) before stimulation with 0.1 U/mL α-
thrombin. (D) Residual platelet aggregation in response to 0.1 U/mL α-thrombin after pre-
incubation of control or Y157C platelets with 5 µM vorapaxar. Data are expressed as a 
percentage of the amplitude of LTA responses in the absence of vorapaxar. The data in B 
and D are means ± SEM (* p≤0.05; ** p≤0.005; ***p≤0.0005; ns=not significant; two way 
ANOVA with Bonferroni post hoc test (B) or StudentÕs t test (F)) and represent 
measurements from at least three experiments in all the Y157C cases and from a minimum 
of six controls. 
!!
Figure 3. Calcium response, integrin αIIbβ3 activation and α-granule release in Y157C 
platelets 
(A-C) Calcium mobilisation responses to PAR4-AP, PAR1-AP and α-thrombin in the three 
Y157C cases and from controls (minimum n=7). Data are presented as the fold increase in 
fluorescence emission following stimulation of the Fluo4-AM loaded platelets expressed 
relative to the fluorescence emission before stimulation. (D) Integrin αIIbβ3 activation 
indicated by PAC1 binding, and α-granule release indicated by P-selectin exposure, in 
response to either 150 µM PAR4-AP (P4-AP) or 5 µM PAR1-AP (P1-AP). Data are 
expressed as the median fluorescence intensity (MFI) of binding of the detecting antibody 
quantified in arbitrary units. Data are means ± SEM from at least four independent 
experiments at each agonist concentration; * p≤0.05; ** p≤0.005; ***p≤0.0005; ns=not 
significant; two way ANOVA with Bonferroni post hoc test.  
!!
Figure 4. PAR4 expression in Y157C platelets.  
(A) Representative Western blot of platelet lysates from Y157C.1 and a control probed with 
anti-PAR4, anti-PAR1 or anti-tubulin antibodies. (B) Total platelet PAR4 and PAR1 
expression measured by densitometry of the principal 70 and 40 KDa immunoreactive bands 
for PAR4 and PAR1 respectively. The data are expressed as relative density units (RDU) 
after normalisation to the tubulin band within each lane. The expression data are from three 
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experiments using Y157C platelets and are presented as means ± SEM; *=p≤0.05, ns=non-
significant; StudentÕs t test. 
!!
Figure 5. PAR4 expression and function in Y157C cells.  
(A) Total PAR4 expression in HEK293 cells transfected with the PAR4 Y157C or PAR4 WT 
CFP-fusion constructs or with empty vector, determined by measuring CFP fluorescence. 
Data are expressed as median fluorescence intensity (MFI) measurements from six 
experiments. (B) Surface PAR4 expression determined by measuring binding of an antibody 
recognising the PAR4 extracellular domain to non-permeabilised HEK293 cells. Data are 
expressed as the MFI measurements from six experiments in cells transfected with 
expression constructs for PAR4 WT (WT) or PAR4 Y157C (Y157C). In all experiments there 
was a total of 10 µg of construct per culture plate. (C) Calcium mobilisation responses to 10-
1000 µM PAR4-AP in Fura2-AM loaded HEK293 cells. Data are expressed as the increase 
in Ca2+ concentration at 100 s after stimulation from three to five experiments. (D) Fold 
increase in [3H] inositol phosphate (IP) accumulation in the presence of lithium chloride to 
prevent IP breakdown, after stimulation with10-100 µM PAR4-AP.  Data are expressed as 
fold increase in [3H] (IP) in a minimum of three experiments. Data are means ± SEM; * 
p≤0.05; ** p≤0.005; ***p≤0.0005; ns=not significant; StudentÕs t test (A and B), two way 
ANOVA with Bonferroni post hoc test (C and D). 
!!
Figure 6. PAR4 Y157C, N56A and Y322A in HEK293 cells 
(A and B) Representative immunofluorescence confocal microscopy images of HEK293 
cells transfected with the PAR4 Y157C or PAR4 WT CFP-fusion expression constructs. CFP 
is represented as green and the endoplasmic reticulum marker calnexin and early endosome 
antigen 1 (EEA1) as red. Areas of co-localisation are indicated by white arrows. (C) Co-
localisation of PAR4-CFP with EEA1 or calnexin quantified by Velocity imaging software and 
expressed as MandersÕ overlap co-efficient.  Data are means ± SEM from 20 cells; *p≤ 0.05; 
one-way ANOVA with DunnettÕs post-test. (D and E) Representative Western blots of lysates 
from HEK293 cells transfected with wild type (WT), Y157C, N56A or Y322A PAR4 (P4) -CFP 
expression constructs probed with anti-CFP or anti-tubulin antibodies. (F) Representative 
immunofluorescence confocal microscopy images of PAR4 WT, PAR4 N56A and PAR4 
Y322A cells. The scale bars represent 10 µm. 
!!
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Table 1. Missense single nucleotide variations in the F2RL3 coding region in 236 cardiac surgery index cases. Variants are expressed 
relative to ENST00000248076 and are annotated to PAR4 topological regions defined in UNIPROT dataset Q96R10 and by using Ballesteros-
Wienstein (BW) generic G protein receptor nomenclature. AT-amino-terminal region; TM-transmembrane domain; ECL- extracellular loop. 
*Global minor allele frequency determined from the Exome Aggregation Consortium Browser 23.    Computational prediction determined from the 
PredictSNP consensus classifier 21. 
 
 
 
 
Position 
 
Predicted 
substitution 
 
Domain  
(BW)  
 
Hom 
cases 
(%)  
 
Het 
cases 
(%) 
 
refSNP 
 
Minor allele 
frequency*  
 
Computational 
annotation   
 
 
Structural 
homology 
modelling  
19:16889707 Ala82Thr  AT/TM 1 (1.37) 0 1 rs139190744 <10-3 Neutral  Neutral 
19:16889821 Ala120Thr  TM2 (2.48) 9 50 rs773902 0.22 Neutral  Neutral 
19:16889933 Tyr157Cys  TM3 (3.33) 0 1 - <10-4 Deleterious  Deleterious 
19:16890319 Ala286Thr TM6 (6.39) 0 1 - <10-4 Neutral Neutral 
19:16890349 Phe296Leu TM6 (6.48) 0 1 rs2227346 <10-3 Deleterious  Uncertain 
19:16800392 Pro310Leu  ECL3 0 4 rs2227376 <10-2 Neutral Neutral 
19:16890466 Val335Leu TM7 (7.48) 0 1 rs1339232968 <10-3 Neutral Neutral 
